| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
|
| Targets |
GABAA receptor[1]
|
|---|---|
| ln Vitro |
2'MeO6MF (100-300 µM; 60 min) slightly shifts the binding of [3H]-flunitrazepam to the synaptic membranes in rat brain by 5–10%. In a concentration-dependent manner, 2'MeO6MF increases [3H]-muscimol binding to rat brain synaptic membranes, resulting in an apparent EC50=20.8 nM and a mean Emax of 219.8%[1]. At recombinant α1β2γ2L GABAA receptors produced in Xenopus M oocytes, 2'MeO6MF (1-300 µM) concentration-dependently improves the response evoked by a low dose of GABA. Without any direct activation, 2'MeO6MF amplifies the response that GABA elicits at recombinant α1β1,3η2L and α1β2 GABAA receptors[1]. Concentration-dependently, 2'MeO6MF (1-10 µM; 60 min) raises tonic inhibitory currents in granule cells[2]. In RAWblueTM macrophage cells, 2'MeO6MF (100-1000 µM; 6.5 h) suppresses the LPS-induced increase in NFkB activity[2].
|
| ln Vivo |
In the elevated plus maze and light/dark tests, 2'MeO6MF (1-100 mg/kg; ip) exhibits anxiolytic-like effects. Higher dosages of MeO6MF produce sedative effects in the holeboard, actimeter, and barbiturate-induced sleep time tests[1]. After a stroke, mice's layer 2/3 pyramidal neurons exhibit an increase in tonic currents when exposed to 30 mg/kg of MeO6MF IV[2]. 2'MeO6MF (0.1-30 mg/kg; ip) protects neurons and improves functional recovery in mice following localized cerebral ischemia[2].
|
| Animal Protocol |
Animal/Disease Models: Male Balb-c mice (8-10 weeks, 25-35 g)[1]
Doses: 1, 10, 30, 100 mg/kg Route of Administration: Ip Experimental Results: No overt acute toxicity was observed. Exerted anxiolytic effects at low doses and sedative effects at high doses without myorelaxant effects. |
| References |
[1]. Karim N, et, al. 2'-Methoxy-6-methylflavone: a novel anxiolytic and sedative with subtype selective activating and modulating actions at GABA(A) receptors. Br J Pharmacol. 2012 Feb;165(4):880-96.
[2]. Clarkson AN, et, al. The flavonoid, 2'-methoxy-6-methylflavone, affords neuroprotection following focal cerebral ischaemia. J Cereb Blood Flow Metab. 2019 Jul;39(7):1266-1282. |
| Molecular Formula |
C17H14O3
|
|---|---|
| Molecular Weight |
266.29
|
| CAS # |
89112-85-6
|
| SMILES |
COC1C=CC=CC=1C1=CC(=O)C2C=C(C)C=CC=2O1
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7553 mL | 18.7765 mL | 37.5530 mL | |
| 5 mM | 0.7511 mL | 3.7553 mL | 7.5106 mL | |
| 10 mM | 0.3755 mL | 1.8777 mL | 3.7553 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
